PMC:7558914 / 13525-14528 JSONTXT

{"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T5","span":{"begin":69,"end":76},"obj":"https://glytoucan.org/Structures/Glycans/G00021MO"},{"id":"T6","span":{"begin":69,"end":76},"obj":"https://glytoucan.org/Structures/Glycans/G54161DR"},{"id":"T7","span":{"begin":116,"end":123},"obj":"https://glytoucan.org/Structures/Glycans/G00021MO"},{"id":"T8","span":{"begin":116,"end":123},"obj":"https://glytoucan.org/Structures/Glycans/G54161DR"},{"id":"T9","span":{"begin":172,"end":179},"obj":"https://glytoucan.org/Structures/Glycans/G00021MO"},{"id":"T10","span":{"begin":172,"end":179},"obj":"https://glytoucan.org/Structures/Glycans/G54161DR"},{"id":"T11","span":{"begin":293,"end":300},"obj":"https://glytoucan.org/Structures/Glycans/G00021MO"},{"id":"T12","span":{"begin":293,"end":300},"obj":"https://glytoucan.org/Structures/Glycans/G54161DR"},{"id":"T13","span":{"begin":533,"end":540},"obj":"https://glytoucan.org/Structures/Glycans/G00021MO"},{"id":"T14","span":{"begin":533,"end":540},"obj":"https://glytoucan.org/Structures/Glycans/G54161DR"},{"id":"T15","span":{"begin":699,"end":706},"obj":"https://glytoucan.org/Structures/Glycans/G00021MO"},{"id":"T16","span":{"begin":699,"end":706},"obj":"https://glytoucan.org/Structures/Glycans/G54161DR"},{"id":"T17","span":{"begin":783,"end":790},"obj":"https://glytoucan.org/Structures/Glycans/G00021MO"},{"id":"T18","span":{"begin":783,"end":790},"obj":"https://glytoucan.org/Structures/Glycans/G54161DR"},{"id":"T19","span":{"begin":946,"end":953},"obj":"https://glytoucan.org/Structures/Glycans/G00021MO"},{"id":"T20","span":{"begin":946,"end":953},"obj":"https://glytoucan.org/Structures/Glycans/G54161DR"}],"text":"All protocols included anticoagulant treatment (low-molecular-weight heparin as the first option and unfractionated heparin as an alternative) and recommended prophylactic heparin during hospitalization. In 8 of the 15 COVID-19 protocols (53.3%), the dose of prophylactic low-molecular-weight heparin was increased if there was a high risk of thrombosis (severe COVID-19 with evidence of cytokine release syndrome, previous venous thromboembolism or acute ischemic artery disease, or D-dimer \u003e3000 ng/mL). In five protocols (33.3%), heparin was increased to therapeutic doses if the condition was critical or if there was a progressive increase in D-dimer levels. All protocols included therapeutic heparin if there was evidence of venous thromboembolism. At discharge, prophylactic heparin was recommended if D-dimer \u003e1500-3000 ng/dL for 7 days or during the time of the expected severe immobilization in seven protocols (46.6%). Adjustments of heparin doses were indicated in the respective protocols."}

{"project":"LitCovid-PubTator","denotations":[{"id":"330","span":{"begin":69,"end":76},"obj":"Chemical"},{"id":"331","span":{"begin":116,"end":123},"obj":"Chemical"},{"id":"332","span":{"begin":172,"end":179},"obj":"Chemical"},{"id":"333","span":{"begin":293,"end":300},"obj":"Chemical"},{"id":"334","span":{"begin":533,"end":540},"obj":"Chemical"},{"id":"335","span":{"begin":699,"end":706},"obj":"Chemical"},{"id":"336","span":{"begin":783,"end":790},"obj":"Chemical"},{"id":"337","span":{"begin":946,"end":953},"obj":"Chemical"},{"id":"338","span":{"begin":219,"end":227},"obj":"Disease"},{"id":"339","span":{"begin":343,"end":353},"obj":"Disease"},{"id":"340","span":{"begin":362,"end":370},"obj":"Disease"},{"id":"341","span":{"begin":424,"end":446},"obj":"Disease"},{"id":"342","span":{"begin":450,"end":479},"obj":"Disease"},{"id":"343","span":{"begin":732,"end":754},"obj":"Disease"}],"attributes":[{"id":"A330","pred":"tao:has_database_id","subj":"330","obj":"MESH:D006493"},{"id":"A331","pred":"tao:has_database_id","subj":"331","obj":"MESH:D006493"},{"id":"A332","pred":"tao:has_database_id","subj":"332","obj":"MESH:D006493"},{"id":"A333","pred":"tao:has_database_id","subj":"333","obj":"MESH:D006493"},{"id":"A334","pred":"tao:has_database_id","subj":"334","obj":"MESH:D006493"},{"id":"A335","pred":"tao:has_database_id","subj":"335","obj":"MESH:D006493"},{"id":"A336","pred":"tao:has_database_id","subj":"336","obj":"MESH:D006493"},{"id":"A337","pred":"tao:has_database_id","subj":"337","obj":"MESH:D006493"},{"id":"A338","pred":"tao:has_database_id","subj":"338","obj":"MESH:C000657245"},{"id":"A339","pred":"tao:has_database_id","subj":"339","obj":"MESH:D013927"},{"id":"A340","pred":"tao:has_database_id","subj":"340","obj":"MESH:C000657245"},{"id":"A341","pred":"tao:has_database_id","subj":"341","obj":"MESH:D054556"},{"id":"A342","pred":"tao:has_database_id","subj":"342","obj":"MESH:D014715"},{"id":"A343","pred":"tao:has_database_id","subj":"343","obj":"MESH:D054556"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"All protocols included anticoagulant treatment (low-molecular-weight heparin as the first option and unfractionated heparin as an alternative) and recommended prophylactic heparin during hospitalization. In 8 of the 15 COVID-19 protocols (53.3%), the dose of prophylactic low-molecular-weight heparin was increased if there was a high risk of thrombosis (severe COVID-19 with evidence of cytokine release syndrome, previous venous thromboembolism or acute ischemic artery disease, or D-dimer \u003e3000 ng/mL). In five protocols (33.3%), heparin was increased to therapeutic doses if the condition was critical or if there was a progressive increase in D-dimer levels. All protocols included therapeutic heparin if there was evidence of venous thromboembolism. At discharge, prophylactic heparin was recommended if D-dimer \u003e1500-3000 ng/dL for 7 days or during the time of the expected severe immobilization in seven protocols (46.6%). Adjustments of heparin doses were indicated in the respective protocols."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T24","span":{"begin":388,"end":413},"obj":"Phenotype"},{"id":"T25","span":{"begin":431,"end":446},"obj":"Phenotype"},{"id":"T26","span":{"begin":739,"end":754},"obj":"Phenotype"}],"attributes":[{"id":"A24","pred":"hp_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A25","pred":"hp_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/HP_0001907"},{"id":"A26","pred":"hp_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/HP_0001907"}],"text":"All protocols included anticoagulant treatment (low-molecular-weight heparin as the first option and unfractionated heparin as an alternative) and recommended prophylactic heparin during hospitalization. In 8 of the 15 COVID-19 protocols (53.3%), the dose of prophylactic low-molecular-weight heparin was increased if there was a high risk of thrombosis (severe COVID-19 with evidence of cytokine release syndrome, previous venous thromboembolism or acute ischemic artery disease, or D-dimer \u003e3000 ng/mL). In five protocols (33.3%), heparin was increased to therapeutic doses if the condition was critical or if there was a progressive increase in D-dimer levels. All protocols included therapeutic heparin if there was evidence of venous thromboembolism. At discharge, prophylactic heparin was recommended if D-dimer \u003e1500-3000 ng/dL for 7 days or during the time of the expected severe immobilization in seven protocols (46.6%). Adjustments of heparin doses were indicated in the respective protocols."}

{"project":"LitCovid-sentences","denotations":[{"id":"T93","span":{"begin":0,"end":203},"obj":"Sentence"},{"id":"T94","span":{"begin":204,"end":505},"obj":"Sentence"},{"id":"T95","span":{"begin":506,"end":663},"obj":"Sentence"},{"id":"T96","span":{"begin":664,"end":755},"obj":"Sentence"},{"id":"T97","span":{"begin":756,"end":930},"obj":"Sentence"},{"id":"T98","span":{"begin":931,"end":1003},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"All protocols included anticoagulant treatment (low-molecular-weight heparin as the first option and unfractionated heparin as an alternative) and recommended prophylactic heparin during hospitalization. In 8 of the 15 COVID-19 protocols (53.3%), the dose of prophylactic low-molecular-weight heparin was increased if there was a high risk of thrombosis (severe COVID-19 with evidence of cytokine release syndrome, previous venous thromboembolism or acute ischemic artery disease, or D-dimer \u003e3000 ng/mL). In five protocols (33.3%), heparin was increased to therapeutic doses if the condition was critical or if there was a progressive increase in D-dimer levels. All protocols included therapeutic heparin if there was evidence of venous thromboembolism. At discharge, prophylactic heparin was recommended if D-dimer \u003e1500-3000 ng/dL for 7 days or during the time of the expected severe immobilization in seven protocols (46.6%). Adjustments of heparin doses were indicated in the respective protocols."}